Breakthrough findings demonstrate a possible target and potential drug treatment to restore memory loss and extend life span in mice with neurodegeneration
“We have treated mice with a new type of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression”
– Professor Andrew Tobin
An international team of scientists has announced a new advance in the fight against Alzheimer’s disease by identifying a new drug target for not only improving symptoms of brain degeneration – but also to extend the life-span of the terminally ill mice.
The four-year study by Medical Research Council (MRC) scientists based at the MRC Toxicology Unit at the University of Leicester is published in the Journal of Clinical Investigation. The study was led by Professor Andrew Tobin alongside colleagues from pharmaceutical company Eli Lilly and Company and the Monash Institute for Pharmaceutical Sciences in Australia. The project was also partly supported by the Wellcome Trust.
Corresponding author Professor Tobin, who alongside the lead researcher Dr Sophie Bradley has since moved from the University of Leicester to the University of Glasgow, said: “The paper describes drug-like molecules that can restore memory loss and slow progression of prion neurodegenerative disease in a manner that relates to the potential of these drugs in human Alzheimer’s disease.
“We have been using mice whose brain cells are progressively dying, similar to what happens in Alzheimer’s disease. This project focuses on a particular protein in the brain, which is proposed to be involved in Alzheimer’s disease, and as such could be a potential target for new drugs.
“We have treated mice with a new class of drug, and found that these drugs can not only improve symptoms of brain degeneration, such as cognitive decline, but can also extend the life-span of these terminally-sick mice.”
The researchers state that drugs which activate this protein receptor in the brain have previously been tested in clinical trials for Alzheimer’s disease, and showed positive results with respect to improving cognition, but the patients experienced a large number of adverse side effects. This new class of drug is more selective and does not cause any side-effects when administered to mice in the study.
The study authors believe that this offers hope in the design of new drugs for improving cognition and extending life span.
Professor Tobin said: “This work may provide important information as to whether this protein is a viable drug target in the treatment of diseases associated with the progressive death of brain cells. This is of great importance to society, based on the fact that the treatment options for Alzheimer’s disease are very limited – there are no cures for Alzheimer’s disease and current treatments are focused on relieving some of the symptoms.
“What we have found is a novel class of drugs, called allosteric ligands, that target a protein called the M1 muscarinic receptor, which is present in the brain. Activating this receptor protein can not only improve cognitive function in mice with progressive brain degeneration, but when administered daily, can extend life span.”
The scientists say the work is important because it focuses on identifying a treatment that not only improves symptoms associated with neurodegeneration, like current treatments, but also identifies a new strategy for slowing disease progression and extending life-span.
Professor Tobin said: “Alzheimer’s disease is the most common form of dementia, and it affects an estimated 850,000 people in the UK alone. There are no treatments that can slow or halt the progression of Alzheimer’s, and patients are treated with drugs which temporarily mask the symptoms of the disease. Often these treatments are associated with side-effects which can limit patient compliance.
“I am proud to be involved in a collaboration with researchers across the world to address one of the world’s major healthcare challenges. Our study opens up avenues for researchers to look at new drugs that treat the symptoms of Alzheimer’s and also slow disease progression.”
Receive an email update when we add a new ALZHEIMERS article.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Biogen reanalyzes studies, presses ahead on Alzheimer’s drugon October 28, 2019 at 11:11 am
FILE – In this Aug. 14, 2018 file photo, Dr. William Burke goes over a PET brain scan at Banner Alzheimers Institute in Phoenix. The drug company Biogen Inc. says it will seek federal approval for a ...
- 'We have to stop it': Generations of family diagnosed with rare, deadly diseaseon October 26, 2019 at 2:58 am
David Russell spent years watching and taking care of other family members, who had a rare genetic disease known as Huntington's Disease.According to KGUN, the disease is a combination of Parkinson's, ...
- Jersey choir helps people with Alzheimerson October 25, 2019 at 9:16 am
Research shows music can benefit people's emotional health, as it uses parts of the brain which are unaffected by the condition. Credit: ITV Channel TV A choir in Jersey is helping people with ...
- Kupuna Life: Looking for a cure to end Alzheimerson October 24, 2019 at 12:09 pm
Seventy-two-year-old Jill McCready of Kane’ohe, is the only person in Hawai’i, and just the 8th person in the world, to receive a particular medicine that could potentially prevent the on-set of the ...
- Come Dress My Table event raises money for Alzheimers' Associationon October 24, 2019 at 12:09 am
LAKE JACKSON — For most of the sponsors at the Come Dress My Table fundraiser, their support had a personal connection. The event, in its second year, invites people to sponsor a table to raise ...
- Biogen Stock Climbed on Surprise Alzheimer’s Drug News. The Effects Could Be Lasting.on October 23, 2019 at 3:34 am
To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com.
- Biogen soars on beat, positive Alzheimers trial resultson October 22, 2019 at 7:41 am
Biogen is up on news its submitting to the Food and Drug Administration an experimental Alzheimer's drug. Yahoo Finance’s Dan Roberts, Anjalee Khemlani and Scott Gamm discuss on YFi AM.
- Biogen Plans Regulatory Filing for Aducanumab in Alzheimers Disease Based on New Analysis of Larger Dataset from Phase 3 Studieson October 22, 2019 at 3:30 am
The positive results of this new analysis were driven primarily by greater exposure to high dose aducanumab in the larger dataset as compared to data available at the time of the futility analysis ...
- Missing man with Alzheimers found safe thanks to ‘guardian angels’on October 19, 2019 at 9:14 pm
At 8:00 a.m. Saturday, Perla Saludes, noticed her father, Alberto Saludes, missing and this truck gone. She was extremely worried because Mr. Saludes has a severe case of Alzheimers and has not driven ...
via Bing News